Abstract

The objectives of this contract are to quantitatively determine drugs and metabolites in biological specimens for pharmacokinetic studies, to quantitatively determine drug metabolites in urine for morphine and cocaine for clinical trials outcome measures and to qualitatively screen for abused substances in urine. In addition, new assay methods shall be developed for drugs and metabolites of which assays do not currently exist. The drugs to be quantified include: cocaine, buprenorphine, morphine, methamphetamine, naltrexone, naloxone, methadone, cyclazocine, lofexidine, baclofen, methylphenidate, GBR12909, acetyl methadol (LAAM) and other drugs under development. The abused substances to be qualitatively screened include opiates, methadone, cocaine (benzoylecgonine), amphetamines, phencyclidine, benzodiazepines etc. -- employing immunoassay methods. The data generated by this contract will be utilized by the NIDA medications Development Division (MDD) in evaluating safety and efficacy of pharmaceutical preparations in the treatment of drug addictions.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research and Development Contracts (N01)
Project #
N01DA078074-004
Application #
6344339
Study Section
Project Start
1997-09-29
Project End
2001-09-28
Budget Start
2000-08-03
Budget End
2001-09-28
Support Year
Fiscal Year
2000
Total Cost
$989,570
Indirect Cost

  Institution

Name
University of Utah
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112

  Publications

Paronis, Carol A; Bergman, Jack (2011) Buprenorphine and opioid antagonism, tolerance, and naltrexone-precipitated withdrawal. J Pharmacol Exp Ther 336:488-95
Chawarski, Marek C; Fiellin, David A; O'Connor, Patrick G et al. (2007) Utility of sweat patch testing for drug use monitoring in outpatient treatment for opiate dependence. J Subst Abuse Treat 33:411-5
Ciraulo, Domenic A; Hitzemann, Robert J; Somoza, Eugene et al. (2006) Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials. J Clin Pharmacol 46:179-92
Strain, Eric C; Moody, David E; Stoller, Kenneth B et al. (2004) Relative bioavailability of different buprenorphine formulations under chronic dosing conditions. Drug Alcohol Depend 74:37-43
Houtsmuller, Elisabeth J; Notes, Lisa D; Newton, Thomas et al. (2004) Transdermal selegiline and intravenous cocaine: safety and interactions. Psychopharmacology (Berl) 172:31-40
Sobel, Bai-Fang X; Sigmon, Stacey C; Walsh, Sharon L et al. (2004) Open-label trial of an injection depot formulation of buprenorphine in opioid detoxification. Drug Alcohol Depend 73:11-22
Moody, D E; Cheever, M L (2001) Evaluation of immunoassays for semiquantitative detection of cocaine and metabolites or heroin and metabolites in extracts of sweat patches. J Anal Toxicol 25:190-7
Spanbauer, A C; Moody, D E; Foltz, R L et al. (2000) A gas chromatographic-positive ion chemical ionization-mass spectrometric method for determination of cocaine, benzoylecgonine, ecgonine methyl ester, and norcocaine in plasma: detection of norcocaine in plasma after oral administration of cocaine. J Anal Toxicol 24:453-5